Cargando…

Levofloxacin-Induced Acute Hyperpigmentation Changes in a Chronic Kidney Disease Patient

Medication-induced cutaneous hyperpigmentation has variable clinical presentations and is dependent on the specific drug involved. Most commonly, an attentive patient observes such changes early in the course; when missed by the patient, such changes are usually noted by an observant clinician. Clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Patil, Shakuntala S., Patil, Sachin M., Campbell, Ryan, Singh, Manisha, Plotkin, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669357/
https://www.ncbi.nlm.nih.gov/pubmed/33224201
http://dx.doi.org/10.1155/2020/6186471
_version_ 1783610552282513408
author Patil, Shakuntala S.
Patil, Sachin M.
Campbell, Ryan
Singh, Manisha
Plotkin, Matthew
author_facet Patil, Shakuntala S.
Patil, Sachin M.
Campbell, Ryan
Singh, Manisha
Plotkin, Matthew
author_sort Patil, Shakuntala S.
collection PubMed
description Medication-induced cutaneous hyperpigmentation has variable clinical presentations and is dependent on the specific drug involved. Most commonly, an attentive patient observes such changes early in the course; when missed by the patient, such changes are usually noted by an observant clinician. Clinical diagnosis can be challenging if the patient is on multiple medications because other causes must be excluded. This condition occurs via multiple mechanisms. Frequently, the pigmentary change is reversible with discontinuation of the drug. Causative medications include nonsteroidal; anti-inflammatory agents, antimalarials, antibiotics, psychotropics, amiodarone, and chemotherapeutic agents. The; antimicrobials responsible for hyperpigmentation are antimalarials, tetracyclines, tigecycline, dapsone, rifampicin, and antiretrovirals such as zidovudine. Sunlight exposure can worsen the pigmentation seen with some of the above antimicrobials (e.g., dapsone). Here, we describe an older adult white woman presenting with acute cutaneous; hyperpigmentation of the bilateral lower extremities while on levofloxacin therapy. Hyperpigmentation resolved after cessation of the agent. Our case highlights this unique acute presentation after only a few days of oral levofloxacin.
format Online
Article
Text
id pubmed-7669357
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-76693572020-11-19 Levofloxacin-Induced Acute Hyperpigmentation Changes in a Chronic Kidney Disease Patient Patil, Shakuntala S. Patil, Sachin M. Campbell, Ryan Singh, Manisha Plotkin, Matthew Case Rep Med Case Report Medication-induced cutaneous hyperpigmentation has variable clinical presentations and is dependent on the specific drug involved. Most commonly, an attentive patient observes such changes early in the course; when missed by the patient, such changes are usually noted by an observant clinician. Clinical diagnosis can be challenging if the patient is on multiple medications because other causes must be excluded. This condition occurs via multiple mechanisms. Frequently, the pigmentary change is reversible with discontinuation of the drug. Causative medications include nonsteroidal; anti-inflammatory agents, antimalarials, antibiotics, psychotropics, amiodarone, and chemotherapeutic agents. The; antimicrobials responsible for hyperpigmentation are antimalarials, tetracyclines, tigecycline, dapsone, rifampicin, and antiretrovirals such as zidovudine. Sunlight exposure can worsen the pigmentation seen with some of the above antimicrobials (e.g., dapsone). Here, we describe an older adult white woman presenting with acute cutaneous; hyperpigmentation of the bilateral lower extremities while on levofloxacin therapy. Hyperpigmentation resolved after cessation of the agent. Our case highlights this unique acute presentation after only a few days of oral levofloxacin. Hindawi 2020-11-07 /pmc/articles/PMC7669357/ /pubmed/33224201 http://dx.doi.org/10.1155/2020/6186471 Text en Copyright © 2020 Shakuntala S. Patil et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Patil, Shakuntala S.
Patil, Sachin M.
Campbell, Ryan
Singh, Manisha
Plotkin, Matthew
Levofloxacin-Induced Acute Hyperpigmentation Changes in a Chronic Kidney Disease Patient
title Levofloxacin-Induced Acute Hyperpigmentation Changes in a Chronic Kidney Disease Patient
title_full Levofloxacin-Induced Acute Hyperpigmentation Changes in a Chronic Kidney Disease Patient
title_fullStr Levofloxacin-Induced Acute Hyperpigmentation Changes in a Chronic Kidney Disease Patient
title_full_unstemmed Levofloxacin-Induced Acute Hyperpigmentation Changes in a Chronic Kidney Disease Patient
title_short Levofloxacin-Induced Acute Hyperpigmentation Changes in a Chronic Kidney Disease Patient
title_sort levofloxacin-induced acute hyperpigmentation changes in a chronic kidney disease patient
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669357/
https://www.ncbi.nlm.nih.gov/pubmed/33224201
http://dx.doi.org/10.1155/2020/6186471
work_keys_str_mv AT patilshakuntalas levofloxacininducedacutehyperpigmentationchangesinachronickidneydiseasepatient
AT patilsachinm levofloxacininducedacutehyperpigmentationchangesinachronickidneydiseasepatient
AT campbellryan levofloxacininducedacutehyperpigmentationchangesinachronickidneydiseasepatient
AT singhmanisha levofloxacininducedacutehyperpigmentationchangesinachronickidneydiseasepatient
AT plotkinmatthew levofloxacininducedacutehyperpigmentationchangesinachronickidneydiseasepatient